GlassScriptPhysician profile
Lindsay M Rodriguez
NPI 1780231134
$1,203.25
in general payments reported to CMS, 2019-2025
24 companies · $225 in 2025
The $225 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $478 · 2022: $158 · 2023: $167 · 2024: $174 · 2025: $225.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $324 · Food and Beverage: $242.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $324.35 |
| Food and Beverage | $242.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $183.13 | 2021-2022 | |
| Incyte Corporation | $131.98 | 2024 | Jakafi |
| Astrazeneca Pharmaceuticals LP | $127.50 | 2021-2023 | Calquence |
| Lilly USA, LLC | $126.03 | 2025 | Verzenio, Jaypirca |
| Progenics Pharmaceuticals, INC. | $66.94 | 2025 | |
| Merck Sharp & Dohme LLC | $56.18 | 2021-2022 | |
| Daiichi Sankyo INC. | $51.95 | 2021 | |
| Janssen Biotech, INC. | $50.06 | 2021 | |
| Novartis Pharmaceuticals Corporation | $45.93 | 2021-2023 | |
| Pharmacyclics LLC, An Abbvie Company | $43.34 | 2021 | |
| Mirati Therapeutics, INC. | $36.16 | 2023 | Krazati |
| Regeneron Healthcare Solutions, INC. | $33.39 | 2021 | |
| Abbvie INC. | $32.27 | 2025 | |
| Pfizer INC. | $29.05 | 2021 | |
| Seagen INC. | $26.60 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genmab U.S., INC. | $25.05 | 2024 | Epkinly |
| Ipsen Biopharmaceuticals, INC | $24.58 | 2022 | |
| G1 Therapeutics, INC. | $19.79 | 2022 | |
| Kite Pharma, INC. | $18.35 | 2021 | |
| Astellas Pharma US INC | $18.24 | 2022 | |
| Coherus Oncology, INC. | $17.08 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $14.26 | 2021 | |
| Beigene USA, INC. | $12.72 | 2021 | |
| Genzyme Corporation | $12.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindsay Rodriguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.